Global Compounding Chemotherapy Market Research Report—Forecast till 2027

Global Compounding Chemotherapy Market Research Report—Forecast till 2027

$4450 – $6250

As per this report, Global Compounding Chemotherapy Market is anticipated to exhibit a CAGR of 6.04% during the review period of 2020 to 2027, to surpass USD 635.58 Million by 2027.

SKU: MRFR210087 Category: Tags: , , , , , , , ,

Description

Global Compounding Chemotherapy Market Overview

Market Dynamics
As per this report, Global Compounding Chemotherapy Market is anticipated to exhibit a CAGR of 6.04% during the review period of 2020 to 2027, to surpass USD 635.58 Million by 2027. The global market growth is driven by the surged incidences of cancer, increasing expenditure on medicine & science and reimbursements, and increased health benefits.

Further, the Compounding chemotherapy market is attributed to the emerging technical advancements, innovations, and strategies to cater to the demands of clinicians.

The global Compounding Chemotherapy Market is expected to witness substantial market growth owing to the highest market contribution in 2019. The rising opioid scarcity is predicted to increase the demand for compounding chemotherapy globally for compounding chemotherapy.

The growth of the market is driven by the benefits of easy-to-use medicines, allowing alternative dosage types to access expired medicines, and making medicines allergen safe. Additionally, hospitals and other healthcare providers are allowing customers to purchase medications that are compounded.

Stem Cell Therapy Market – Forecast till 2027

Market Segmentation
Global Compounding Chemotherapy Market has been classified in terms of Dose, Compounding Type, Delivery Method, Sterility, Technology, Compounder Type, and Application.

Global Compounding Chemotherapy Market in terms of the dose has been bifurcated into chemotherapeutic and non-chemotherapeutics. The global compounding chemotherapy market, by compounding type, has been classified into pharmaceutical ingredient alteration (PIA), currently unavailable pharmaceutical manufacturing (CUPM), and pharmaceutical dosage alteration (PDA).

The PDA segment is evaluated to register a fastest growth rate during the forecast period. Based on the delivery method, the global market has been divided into gravimetric automated compounding devices (weight-based) and volumetric automated compounding devices (volume-based).

Based on the global compounding chemotherapy market, has been bifurcated into sterile and non-sterile. The sterile is expected to lead the market owing to the largest share of 56.0% in 2019.

Regional Analysis
Region-specific analysis of Global Compounding Chemotherapy Market, based on region, has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is likely to drive the largest market owing to the surge in cancer patients, an increase in health care rates, and the growing requirement for treatment with chemotherapy in the area. The regional market has been classified into North America and Latin America, with the North American market further divided into the US and Canada.

The European compounding chemotherapy market has been classified into Western Europe and Eastern Europe. The Western Europe compounding chemotherapy market is spread across Germany, France, the UK, Italy, Spain, and the Rest of Western Europe.

The regional market has been driven by the government-based research program aimed at curing the rising number of cancer cases and increased health spending pushes the growth of the regional chemotherapy market.

Major Players
The Key Players in the Global Compounding Chemotherapy Market include Braun Melsungen AG, Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, Millers Pharmacy, Comecer S.P.A., Omnicell, Icon group, Dedalus Group, Arxium, Sterline S.R.L., and Loccioni.

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.

Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENT 1 EXECUTIVE SUMMARY 2 MARKET INTRODUCTION 2.1 DEFINITION 21 2.2 SCOPE OF THE STUDY 21 2.3 RESEARCH OBJECTIVE 21 2.4 MARKET STRUCTURE 22 2.5 ASSUMPTIONS & LIMITATIONS 23 3 RESEARCH METHODOLOGY 3.1 DATA MINING 24 3.2 SECONDARY RESEARCH 25 3.3 PRIMARY RESEARCH 26 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 27 3.5 FORECASTING TECHNIQUES 28 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 29 3.6.1 BOTTOM-UP APPROACH 30 3.6.2 TOP-DOWN APPROACH 30 3.7 DATA TRIANGULATION 31 3.8 VALIDATION 31 4 MARKET DYNAMICS 4.1 OVERVIEW 32 4.2 DRIVERS 33 4.2.1 TECHNOLOGICAL DEVELOPMENTS AND GROUND-BREAKING TECHNIQUES 33 4.2.2 INCREASE IN DRUGS SHORTAGE COMPRISING CANCER MEDICINES 34 4.2.3 RISE IN AWARENESS AND ADAPTATION OF NEW TECHNOLOGIES AMONG CANCER HOSPITALS 34 4.2.4 RISING PREVALENCE OF CANCER PATIENTS 34 4.3 RESTRAINTS 36 4.3.1 DEARTH OF PRACTICED PHARMACISTS AND LAB TECHNICIANS 36 4.4 OPPORTUNITIES 36 4.4.1 NEW PRODUCT INNOVATIONS 36 4.4.2 RISE IN PARTNERSHIPS & COLLABORATIONS 36 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 37 5.1.1 R&D AND DESIGNING 37 5.1.2 MANUFACTURING 38 5.1.3 DISTRIBUTION & SALES 38 5.1.4 POST SALES SERVICES 38 5.2 PORTER’S FIVE FORCES MODEL 38 5.2.1 BARGAINING POWER OF SUPPLIERS 39 5.2.2 BARGAINING POWER OF BUYERS 39 5.2.3 THREAT OF NEW ENTRANTS 39 5.2.4 THREAT OF SUBSTITUTES 40 5.2.5 INTENSITY OF RIVALRY 40 5.3 COVID-19 IMPACT ANALYSIS 40 5.3.1 IMPACT ON SUPPLY CHAIN 41 5.3.2 IMPACT ON PRODUCTION 41 5.3.3 IMPACT ON REGIONS 41 5.3.4 DEMAND-SUPPLY GAP ANALYSIS 41 5.4 LIST OF POTENTIAL CUSTOMERS 42 6 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE 6.1 OVERVIEW 45 6.2 CHEMOTHERAPEUTIC 46 6.3 NON-CHEMOTHERAPEUTICS 46 7 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE 7.1 OVERVIEW 47 7.2 PHARMACEUTICAL INGREDIENT ALTERATION (PIA) 48 7.3 CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING (CUPM) 49 7.4 PHARMACEUTICAL DOSAGE ALTERATION (PDA) 50 8 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD 8.1 OVERVIEW 51 8.2 GRAVIMETRIC AUTOMATED COMPOUNDING DEVICE (WEIGHT-BASED) 52 8.3 VOLUMETRIC AUTOMATED COMPOUNDING DEVICE (VOLUME-BASED) 53 9 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY 9.1 OVERVIEW 54 9.2 STERILE 55 9.3 NON-STERILE 56 10 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY 10.1 OVERVIEW 57 10.2 WITH ROBOTIC ARMS 58 10.3 WITHOUT ROBOTIC ARMS 59 11 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE 11.1 OVERVIEW 60 11.2 PHARMODUCT 61 11.3 EQUASHIELD PRO 61 11.4 MEDIMIX 61 11.5 INTEGRA 61 11.6 OTHERS 61 12 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION 12.1 OVERVIEW 62 12.2 BREAST CANCER 63 12.3 BLOOD CANCER 64 12.4 PROSTATE CANCER 65 12.5 GASTROINTESTINAL CANCER 66 12.6 RESPIRATORY/LUNG CANCER 66 12.7 OTHERS 67 13 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY REGION 13.1 OVERVIEW 68 13.2 AMERICAS 69 13.2.1 NORTH AMERICA 73 13.2.1.1 US 76 13.2.1.2 CANADA 79 13.2.2 LATIN AMERICA 82 13.2.2.1 BRAZIL 85 13.2.2.2 REST OF LATIN AMERICA 88 13.3 EUROPE 92 13.3.1 WESTERN EUROPE 96 13.3.1.1 GERMANY 99 13.3.1.2 FRANCE 102 13.3.1.3 UK 105 13.3.1.4 ITALY 108 13.3.1.5 SPAIN 111 13.3.1.6 REST OF WESTERN EUROPE 114 13.3.2 EASTERN EUROPE 117 13.4 ASIA-PACIFIC 121 13.4.1 CHINA 125 13.4.2 JAPAN 127 13.4.3 INDIA 130 13.4.4 AUSTRALIA 133 13.4.5 SOUTH KOREA 136 13.4.6 REST OF ASIA-PACIFIC 139 13.5 MIDDLE EAST & AFRICA 142 13.5.1 MIDDLE EAST 145 13.5.2 AFRICA 148 14 COMPETITIVE LANDSCAPE 14.1 OVERVIEW 151 14.2 COMPETITOR DASHBOARD 152 14.3 MAJOR GROWTH STRATEGY IN THE GLOBAL COMPOUNDING CHEMOTHERAPY MARKET 153 14.4 MARKET SHARE ANALYSIS 153 14.5 COMPETITIVE BENCHMARKING 154 14.6 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL COMPOUNDING CHEMOTHERAPY MARKET 155 14.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 156 14.8 KEY DEVELOPMENTS & GROWTH STRATEGIES 156 14.8.1 ACQUISITION 156 14.8.2 COLLABORATION 156 14.8.3 PARTNERSHIP 157 14.8.4 COLLABORATION 157 15 COMPANY PROFILE 15.1 B. BRAUN MELSUNGEN AG 158 15.1.1 COMPANY OVERVIEW 158 15.1.2 FINANCIAL OVERVIEW 158 15.1.3 PRODUCTS/SERVICES OFFERED 159 15.1.4 KEY DEVELOPMENTS 159 15.1.5 SWOT ANALYSIS 160 15.1.6 KEY STRATEGIES 160 15.2 PFIZER INC. 161 15.2.1 COMPANY OVERVIEW 161 15.2.2 FINANCIAL OVERVIEW 161 15.2.3 PRODUCTS/SERVICES OFFERED 162 15.2.4 KEY DEVELOPMENTS 162 15.2.5 SWOT ANALYSIS 162 15.2.6 KEY STRATEGIES 163 15.3 BAXTER 164 15.3.1 COMPANY OVERVIEW 164 15.3.2 FINANCIAL OVERVIEW 164 15.3.3 PRODUCTS/SERVICES OFFERED 165 15.3.4 KEY DEVELOPMENTS 165 15.3.5 SWOT ANALYSIS 165 15.3.6 KEY STRATEGIES 166 15.4 GRIFOLS, S.A. 167 15.4.1 COMPANY OVERVIEW 167 15.4.2 FINANCIAL OVERVIEW 167 15.4.3 PRODUCTS/SERVICES OFFERED 168 15.4.4 KEY DEVELOPMENTS 168 15.4.5 SWOT ANALYSIS 168 15.4.6 KEY STRATEGIES 169 15.5 THE METRIX COMPANY 170 15.5.1 COMPANY OVERVIEW 170 15.5.2 FINANCIAL OVERVIEW 170 15.5.3 PRODUCTS/SERVICES OFFERED 170 15.5.4 KEY DEVELOPMENTS 170 15.5.5 SWOT ANALYSIS 171 15.5.6 KEY STRATEGIES 171 15.6 ADDED PHARMA 172 15.6.1 COMPANY OVERVIEW 172 15.6.2 FINANCIAL OVERVIEW 172 15.6.3 PRODUCTS/SERVICES OFFERED 172 15.6.4 KEY DEVELOPMENTS 173 15.6.5 SWOT ANALYSIS 173 15.6.6 KEY STRATEGIES 173 15.7 EQUASHIELD 174 15.7.1 COMPANY OVERVIEW 174 15.7.2 FINANCIAL OVERVIEW 174 15.7.3 PRODUCTS/SERVICES OFFERED 174 15.7.4 KEY DEVELOPMENTS 174 15.7.5 SWOT ANALYSIS 175 15.7.6 KEY STRATEGIES 175 15.8 MILLERS PHARMACY 176 15.8.1 COMPANY OVERVIEW 176 15.8.2 FINANCIAL OVERVIEW 176 15.8.3 PRODUCTS/SERVICES OFFERED 176 15.8.4 KEY DEVELOPMENTS 176 15.8.5 SWOT ANALYSIS 177 15.8.6 KEY STRATEGIES 177 15.9 COMECER S.P.A. 178 15.9.1 COMPANY OVERVIEW 178 15.9.2 FINANCIAL OVERVIEW 178 15.9.3 PRODUCTS/SERVICES OFFERED 178 15.9.4 SWOT ANALYSIS 179 15.9.5 KEY STRATEGIES 179 15.10 OMNICELL 180 15.10.1 COMPANY OVERVIEW 180 15.10.2 FINANCIAL OVERVIEW 180 15.10.3 PRODUCTS/SERVICES OFFERED 180 15.10.4 SWOT ANALYSIS 181 15.10.5 KEY STRATEGIES 181 15.11 ICON GROUP 182 15.11.1 COMPANY OVERVIEW 182 15.11.2 FINANCIAL OVERVIEW 182 15.11.3 PRODUCTS/SERVICES OFFERED 182 15.11.4 KEY DEVELOPMENTS 183 15.11.5 SWOT ANALYSIS 184 15.11.6 KEY STRATEGIES 184 15.12 DEDALUS GROUP 185 15.12.1 COMPANY OVERVIEW 185 15.12.2 FINANCIAL OVERVIEW 185 15.12.3 PRODUCTS/SERVICES OFFERED 185 15.12.4 KEY DEVELOPMENTS 185 15.12.5 SWOT ANALYSIS 186 15.12.6 KEY STRATEGIES 186 15.13 ARXIUM 187 15.13.1 COMPANY OVERVIEW 187 15.13.2 FINANCIAL OVERVIEW 187 15.13.3 PRODUCTS/SERVICES OFFERED 187 15.13.4 KEY DEVELOPMENTS 187 15.13.5 SWOT ANALYSIS 188 15.13.6 KEY STRATEGIES 188 15.14 STERILINE S.R.L. 189 15.14.1 COMPANY OVERVIEW 189 15.14.2 FINANCIAL OVERVIEW 189 15.14.3 PRODUCTS/SERVICES OFFERED 189 15.14.4 KEY DEVELOPMENTS 189 15.14.5 SWOT ANALYSIS 190 15.14.6 KEY STRATEGIES 190 15.15 LOCCIONI 191 15.15.1 COMPANY OVERVIEW 191 15.15.2 PRODUCTS/SERVICES OFFERED 191 15.15.3 KEY DEVELOPMENTS 191 15.15.4 SWOT ANALYSIS 192 15.15.5 KEY STRATEGIES 192 16 APPENDIX 16.1 REFERENCES 193 16.2 RELATED REPORTS 193

Related products